The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Aligning Science Across Parkinson's, 2023(Supplement) Exploring the Mechanisms by which Co-pathologies Drive Neuroinflammation and Progression in Parkinson’s Disease
Study Rationale: Although Parkinson’s disease (PD) is considered a synucleinopathy, the clinical progression of PD is driven by additional pathological proteins such as tau and beta amyloid. We...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Using a Virally Encoded, Single-chain Antibody as a Noninvasive Gene Therapy for Parkinson’s Disease
Study Rationale: The main pathological hallmarks of Parkinson’s disease (PD) are the degeneration of dopamine-producing brain cells and the accumulation of protein aggregates containing misfolded...
-
Research Grant, 2023Establishing the South Carolina Parkinson’s Disease Registry
Study Rationale: The South Carolina Parkinson’s Disease (PD) Registry aims to collect data on the incidence and prevalence of PD in the state. Established by South Carolina Parkinson's Disease...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Discovering Ocular Biomarkers of Parkinson’s Disease
Study Rationale: Early detection of Parksinson’s disease (PD) leads to improved care and better quality of life. However, the current methods for diagnosing PD, physical examination and brain imaging...
-
Research Grant, 2023Preclinical Development of Disease-modifying Therapies for Treating Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by the hallmark accumulation of toxic clumps of alpha-synuclein, particularly a modified form of the protein called pS129. Acurex has...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Examining the Role of LRRK2 and Glucocerebrosidase Dysfunction in Exosome-mediated Release of the Lipid Biomarker Bis(monocylglycero)phosphate in Parkinson's Disease
Study Rationale: Mutations in LRRK2 and GBA1 (which encodes the enzyme glucocerebrosidase, or GCase) are among the most common genetic risk factors for Parkinson’s disease (PD). Individuals with these...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.